Company intelligence / Profile preview
Jiangsu Shengdi
Lianyungang, Jiangsu, Chinahrs.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Jiangsu Shengdi is a core subsidiary of Jiangsu Hengrui Pharmaceuticals, responsible for much of the group's innovative drug R&D and manufacturing. It has successfully commercialized multiple innovative drugs in China, including the blockbuster PD-1 inhibitor AiRuiKa (camrelizumab) and the HER2-targeted small molecule AiRuiNi (pyrotinib). Its pipeline is one of the most extensive in China, with late-stage programs in ADCs, JAK inhibitors, and bispecific antibodies.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateBispecific monoclonal antibodyRecombinant fusion proteinPeptide
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
TG TherapeuticsMerck KGaAElevar TherapeuticsCrystalGenomics
Beyond the preview
Go deeper on Jiangsu Shengdi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu Shengdi.